ATAGI have now recommended that adolescents aged 12-17 years can receive the Novavax COVID-19 vaccine for their primary course of COVID-19 vaccination. This recommendation provides another vaccine brand option, in addition to Pfizer and Moderna, for individuals in this age group.
A Novavax primary schedule consists of 2 doses, administered 8 weeks apart. Those with severe immunocompromise should receive 3 doses.
Whilst Novavax is not currently registered for use as a booster dose in adolescents aged 12-17 years, ATAGI advises that it may be used for this purpose, when Pfizer is not suitable for that person.
To read the recommendations in full please follow the link below.
ATAGI recommendations on the use of the Novavax vaccine for adolescents aged 12-17 years.